Objectives: Breast tumor resembling tall cell variant of papillary thyroid carcinoma (BTRPTC) is a rare breast lesion that is unrelated to thyroid carcinoma. Morphologically, it shows a solid papillary lesion with bland cytology, eosinophilic/amphophilic secretions, nuclear grooves, reversal of nuclear polarity (recently described), and nuclear inclusions. Clinical course is often uneventful with few exceptions reported in the literature. Herein, we report three additional cases.
Methods: Immunohistochemical staining and next-generation sequencing was performed on all three cases.
Results:
The lesional cells on all cases were positive for cytokeratin 5 and S100, with weak expression/lack of estrogen receptor. No staining was observed for myoepithelial markers (p63 and myosin heavy chain) around the lesion. IDH2 mutations were identified in two cases at nucleotide 172 (cases 1 and 3). ATM gene mutation was identified in cases 2 and 3 and PIK3CA mutation in case 3. All patients are currently without disease.
Conclusions: BTRPTC is a slow-growing neoplastic lesion that needs to be distinguished from other papillary lesions for optimizing therapy.
Breast tumor resembling tall cell variant of papillary thyroid carcinoma (BTRPTC) was first reported as a series of five cases by Eusebi et al 1 in 2003 . These cases showed morphologic features that resembled papillary thyroid carcinoma. The cells were described as follows: columnar, oxyphilic, arranged in nests, papillae, and having a follicle-like structure. Nuclear grooves were easily identified, and two cases also showed nuclear inclusions. None of these cases had an associated thyroid malignancy. The cases were also reported to be negative for thyroid-specific markers. Since then, eight more cases have been reported in peer-reviewed
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publications. [2] [3] [4] [5] [6] An additional 13 cases have been presented in abstract form by Chiang et al 7, 8 at the United States and Canadian Academy of Pathology (USCAP) meeting in 2014, with a further update of the same cases at the American Association of Cancer Research (AACR) meeting in 2016. The prior reported cases are summarized in Table 1 . The common theme for the reported cases is the presence of a papillary architecture with cells arranged in solid nests and showing a varying degree of nuclear features that are associated with papillary thyroid cancers. None of the cases have been reported to be positive for thyroid markers or associated thyroid malignancy. This has prompted some investigators to propose changing the name of the entity by removing the term thyroid carcinoma. 5 The immunohistochemical markers reported on each case are variable, but most show lack of myoepithelial markers in the periphery of the lesion, indicating that these tumors are not limited to the breast ducts. Molecular studies reported by Chiang et al 7, 8 show some recurrent mutations, indicating the neoplastic potential of this entity. We herein report three cases of BTRPTC with a characteristic immunohistochemical profile using myoepithelial markers, cytokeratin (CK) 5, and estrogen receptor (ER) to aid in the differential diagnosis from other papillary lesions. We also report the tumor's mutation profile using next-generation sequencing.
Materials and Methods
We came across three difficult-to-characterize "atypical papillary lesions" in routine practice that have significant similarities to the published morphologic description for BTRPTC. These cases are described in detail.
Immunohistochemical stains were performed using automated immunostainers. Next-generation sequencing was performed on all three cases at our institutional molecular and genomic pathology laboratory (http://mgp.upmc.com/Applications/mgp/Home/ Test/PCMP_Details). Genomic DNA was used for multiplex polymerase chain reaction amplification of 207 amplicons, which target 2,800 mutations in 50 key cancer genes using the Ion AmpliSeq Cancer Hotspot Panel v2 with the Ion AmpliSeq Library Kit 2.0 (Life Technologies, Carlsbad, CA). Amplicons were barcoded, ligated with specific adapters, and purified. A final check of library preparation was performed using the Agilent 2200 Tapestation (Agilent, Santa Clara, CA). The Ion OneTouch2 and OneTouch ES were used to prepare and enrich Ion Sphere Particle templates for sequencing on a 318v2 semiconductor chip (Life Technologies). Next-generation bidirectional sequencing was performed on the Ion Torrent Personal Genome Machine and analyzed with the Torrent Suite Software v.4.4.3 with Variant Caller plug-in (Life Technologies). Variant annotation and reporting were performed with SeqReporter software (University of Pittsburgh Medical Center). 9 
Results

Case 1
At the time of surgery, the patient was a 65-year-old woman with a nodular subcentimeter lesion of the breast. She had history of similar lesions 7 and 2 years ago but was uncertain if those were completely excised. The slides were received in consultation. In the biopsy specimen and subsequent resection, the microscopic sections demonstrated a nodular papillary lesion with "haphazard" proliferation of the epithelium. These papillary "hyperplastic"-appearing nodules were separated by fibrotic stroma. The overall lowmagnification appearance was reminiscent of solid papillary carcinoma, but the epithelial cells were not round and "monotonous" enough to render that diagnosis Image 1 . The proliferating epithelium itself appeared bland, and many cells showed nuclear grooves. In some areas around the epithelial-stromal fibrotic zone, the nuclei appeared to be present away from the stromal surface of the cell (reversed nuclear polarity). Several immunohistochemical myoepithelial markers were performed. No peripheral staining was observed with p63 and smooth muscle myosin heavy chain (SMMHC), but calponin highlighted a patchy myoepithelial cell layer. Smooth muscle actin showed slightly more staining around the epithelial cell nests. The lesional cells showed patchy reactivity for S100. The proliferative epithelium showed diffuse reactivity for CK5/6. The proliferating epithelium was negative for ER and progesterone receptor (PR). Despite negativity for p63 and SMMHC, a diagnosis of invasion or solid papillary carcinoma could not be made due to the bland and hyperplastic-appearing cytomorphologic features of the proliferating epithelium. Furthermore, negativity for hormone receptors and reactivity for high-molecular-weight keratins CK5/6 was also against the diagnosis of solid papillary carcinoma. Therefore, a diagnosis of nodular papillary lesion with epithelial hyperplasia and sclerosis was made with a comment suggesting a conservative follow-up, as the lesion was completely excised. Next-generation sequencing performed on the lesion showed the following sequence variant: IDH2, c.515G>C, pR172T. The mutation was found at 23% of allele frequency or in approximately 46% of cells with a heterozygous mutation. The patient was without disease for 19 months at the last follow-up.
Case 2
This case was reviewed at our institution since the patient was seeking treatment based on outside diagnosis of an atypical papillary lesion. A 77-year-old woman was identified with a 1.7-cm left breast mass at 3:00, 8 cm from the nipple on screening studies. The core biopsy specimen of the lesion showed a lobulated solid papillary lesion intersected by few thick fibrous bands. The lesional proliferating cells showed a crowded haphazard growth Image 2 . Many areas showed inspissated eosinophilic/amphophilic secretions. The cells were cytologically bland, with many showing nuclear grooves. Reversed nuclear polarity was noted in some areas. A few nuclei contained nuclear inclusion. Myoepithelial cell staining (as assessed by p63, SMMHC, and calponin) was absent around the lesion. ER showed patchy, generally weak staining of the lesional cells. S100 was positive in the lesional cells. CK5 showed diffuse strong staining of the lesional cells. The lesional cells were negative for both thyroglobulin and TTF-1. The Ki-67 proliferation index was around 5%. Due to abundant secretions, fluorescence in situ hybridization (FISH) for ETS variant gene 6 (ETV6) gene rearrangement was performed to rule out secretory carcinoma and was negative. The lesional morphology and immunohistochemical profile were compatible with the diagnosis of BTRPTC. After discussion and review of the literature with the multidisciplinary tumor board, a decision was made to excise the lesion with negative margins but to avoid a sentinel node-mapping procedure at the current time. The excision was performed 3.5 months after core biopsy, and the specimen showed the residual lesion with similar findings. There was no increase in tumor size. Repeat staining for myoepithelial cell markers showed only focal staining around the tumor with p63 and SMMHC. A few lesional cells also stained with SMMHC. Additional immunohistochemical stains showed reactivity for AE1/AE3, CAM 5.2, EMA, CK7, CK14 (scattered), CK17 (patchy), S100 (moderate), PR (focal), androgen receptor (patchy), GATA-3 (moderate), GCDFP-15 (patchy), and mammaglobin (diffuse strong). The tumor cells were negative for CK20. Interestingly, the tumor was flanked by intraductal papilloma(s) with usual ductal hyperplasia. The papilloma(s) also showed unusual secretions that were similar to the secretions within the BTRPTC. The papilloma(s) showed a peripheral layer of myoepithelial cells, and the usual hyperplasia within the papilloma was positive for CK5.
In addition, focal atypical ductal hyperplasia was also identified, which was negative for CK5 and showed strong reactivity for ER. Next-generation sequencing was performed on the tumor as well as the flanking papilloma in the resection specimen. The tumor showed the following sequence variant: Ataxia-Telangiectasia Mutated (ATM), c.1009C>T, p.R337C (4% allele frequency or 8% of cells with heterozygous mutation). The papilloma flanking the tumor showed the following sequence variant: Phosphatidylinositol 3-Kinase Catalytic Alpha (PIK3CA), c.3145G>C, p.G1049R (10% allele frequency or 20% of cells with heterozygous mutation). Both the tumor and the papilloma showed DNA copy number changes suggestive of proto-oncogene receptor tyrosine kinase (KIT) gene, exon 18 deletion.
Case 3
This 48-year-old patient underwent bilateral magnetic resonance imaging (MRI) for extent of disease after a recent diagnosis of invasive ductal carcinoma of the left breast (ER negative, PR weakly positive, human epidermal growth factor receptor 2 [HER2] positive, Ki-67 labeling index of 60%). The MRI showed a 1.2-cm mass at 12:00 in the contralateral right breast, which was biopsied. The core biopsy specimen showed an extensively proliferative nodular lesion Image 3 . The proliferative epithelium showed a solid papillary growth pattern, but unlike solid papillary carcinoma, the epithelium appeared "hyperplastic" rather than round and monotonous. Some areas showed glandular lumens with eosinophilic secretory material (colloid-like). The proliferating epithelium also showed scattered nuclear grooves, and reversed nuclear polarity was identified. The myoepithelial E F cell markers for p63 and SMMHC were completely negative around the proliferative epithelium. Rare scattered reactivity was noted for ER within the proliferative epithelium. However, CK5 was diffusely and strongly positive within the proliferative epithelium. The lesional cells were also positive for S100. The biopsy specimen was interpreted as atypical papillary lesion with a comment indicating that the "papillary lesion is considered atypical not because of the proliferative component (which actually stains with cytokeratin 5 and likely represents florid ductal epithelial hyperplasia), but due to the absence of myoepithelial cells around the lesion." Therefore, a complete excision of the lesion was recommended. Following completion of trastuzumab-based neoadjuvant chemotherapy for the patient's concurrent left breast carcinoma, the patient underwent resection of the tumor bed on the left side and also excision of the right breast lesion. The patient had pathologic complete response to neoadjuvant chemotherapy for her cancer in the left breast. The right breast lesion showed the residual BTRPTC and areas of sclerosed papilloma without definitive evidence of therapy-related changes. The patient was without disease for 19 months at the last follow-up. Next-generation sequencing performed on the right breast BTRPTC showed the following sequence variants: PIK3CA, c.3140A>G p.H1047R (29% of allele frequency or 58% of cells with heterozygous mutation); IDH2, c.516G>T p.R172S (19% allele frequency); ATM, c.1229T>C p.V410A (60% allele frequency); and protooncogene receptor tyrosine kinase (MET), c.2962C>T p.R988C (48% allele frequency). Based on allelic frequency, the last two variants can be either germline or somatic.
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Image 2 Case 2. The core biopsy specimen shows a lobulated solid papillary neoplasm with thick intersecting fibrous strands (A, H&E, Â20). Secretory material is prominently seen (B, H&E, Â100). The cells show bland cytology with grooved nuclei arranged away from the stromal surface (C, H&E, Â400). Scattered nuclear inclusions are identified (D, H&E, Â400).
The clinical and immunohistochemical features of all the three cases are summarized in Table 2 and Table 3 , respectively. Discussion BTRPTC is a rare breast lesion first described in 2003 by Eusebi and colleagues. 1 Contrary to the suggested name, BTRPTC has never been shown to be positive for thyroid markers. The first report and subsequent reports describe/classify BTRPTC as a "papillary" lesion. [1] [2] [3] [4] [5] [6] How much the lesion resembles papillary thyroid carcinoma is based not only on tumor morphology but also on the type and scope of a pathologist's practice (ie, a general pathologist would see more resemblance to papillary thyroid carcinoma, but a breast pathologist would see this as an "atypical" papillary breast lesion). The three cases in this report were not referred to us as tumors resembling thyroid cancer but rather as unusual papillary breast lesions that are difficult to classify. Therefore, it is important to highlight the similarities and differences of BTRPTC from the currently accepted terminology for papillary lesions of the breast. At the current time, papillary lesions of the breast are categorized as intraductal papilloma (which often shows associated usual ductal hyperplasia and sclerosis), papilloma with atypical ductal or atypical lobular hyperplasia (often termed atypical papilloma), ductal carcinoma in situ (DCIS) involving a papilloma (ie, DCIS secondarily involving a
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Image 2 (cont) There is an absence of staining around the lesion with p63 (E, Â100). The lesional cells show weak patchy reactivity for estrogen receptor (F, Â200). Strong staining is identified with cytokeratin 5 (G, Â100). The lesional cells are also positive for S100 (H, Â100).
preexisting papilloma), papillary DCIS (ie, when the lesion is DCIS from inception), encapsulated papillary carcinoma (EPC, also known as intracystic papillary carcinoma), solid papillary carcinoma (SPC), and invasive papillary carcinoma. [10] [11] [12] [13] [14] Although most of these lesions can be identified on an H&E section with ease, pathologists often use immunohistochemistry for lesions that are difficult to classify. The usual ductal hyperplasia associated with intraductal papilloma shows a papillary lesion with thick-walled blood vessels and proliferation of epithelium that demonstrate "streaming." Occasionally, the proliferation extensively distends the duct with attenuation of myoepithelial cells, but myoepithelial cells are almost always identified on immunohistochemical stains. The proliferative epithelium in papilloma stains diffusely and strongly with basal-type cytokeratins (CK5 or CK5/6) and demonstrate weak/patchy to absent staining for ER. 15 However, atypical ductal hyperplasia (within or outside of papilloma) shows a reverse staining pattern (ie, negative for CK5 and CK5/6 but strong ER expression). 15 This expression profile is maintained in DCIS involving a papilloma, papillary DCIS, EPC, and SPC. 16 In addition, EPC and SPC also lack myoepithelial cell staining in the periphery of the lesion. 10 Therefore, a strong CK5-positive and weak to negative ER profile is considered a "hyperplastic" profile, and a CK5-negative and strong ER-positive profile is considered an "atypical/neoplastic" profile. Comparing BTRPTC with these papillary lesions, BTRPTCs show a "hyperplastic" profile of the lesional cells similar to papillomas with hyperplasia but also lack a myoepithelial cell layer around the lesion as in encapsulated and solid papillary carcinomas Table 4 . The overall immunohistochemical profile of the BTRPTC indicates a mixed epithelial and myoepithelial profile since the
Image 3 (cont) There is an absence of staining around the lesion with p63 (E, Â100). Smooth muscle myosin heavy chain staining is also absent around the lesion (F, Â100). The proliferating cells are diffusely and strongly positive for cytokeratin 5 (G, Â40). Rare cells are reactive for estrogen receptor (H, Â100). lesional cells are positive not only for breast epithelial markers but also for high-molecular-weight keratins, S100, and myosin heavy chain (in case 2), which are known to stain myoepithelial cells. The exact origin of BTRPTC is uncertain, but the presence of papilloma in close vicinity in two cases (cases 2 and 3) and sharing of molecular features in case 2 (findings suggestive of KIT gene exon 18 deletion in both BTRPTC and papilloma) suggest close kinship with intraductal papilloma. The bland cytomorphologic features and the hybrid immunohistochemical features (mixed epithelial and myoepithelial) in BTRPTC are confusing in predicting the clinical behavior of the lesion. The first report of BTRPTC described five cases with 1-to 2-cm lesions that were cured by wide local excision. 1 The subsequently reported eight additional cases were described to have similar clinical and morphologic findings except for two cases. [2] [3] [4] [5] [6] The case of an 80-year-old woman reported by Tosi et al 6 as having intramammary metastasis is questionable. The photomicrograph shown in the article shows lymphoid infiltrate, but a definite lymph node capsule is lacking. The case by CameselleTeijeiro et al 2 was reported as a stage IIIC tumor with eventual bone metastasis that showed DCIS with comedonecrosis and positivity for both ER and PR. The black and white photomicrographs in the article are hard to discern, but the description matches more with a usual ER-positive breast cancer rather than BTRPTC. Apart from these two cases, the reported follow-up on other cases has been uneventful. The 13 cases reported in an abstract form by Chiang et al 7, 8 do not have follow-up information available. The three cases we describe in this report support categorization of BTRPTC as a distinct entity and also shed some light on clinical association and outcome. In the first case, it is uncertain if the lesion was entirely removed at first occurrence. The lesion recurred to form a nodule (2 years after last intervention), which suggests the neoplastic potential of this lesion. However, the patient has been disease free at 19 months since last complete excision. In the second case, the lesion was incidentally discovered on a screening procedure. The excision was delayed for 3.5 months, but the lesion did not grow from its original size at diagnosis. The Ki-67 proliferation index was around 5%. These findings indicate a slow-growing neoplastic lesion. In the third case, the lesion was again incidentally discovered during the workup of a concurrently diagnosed contralateral ER-negative, HER2-positive invasive ductal carcinoma. The excision was performed several months later after neoadjuvant chemotherapy for contralateral cancer. The lesion (BTRPTC) did not grow in size since diagnosis, and there was no effect of chemotherapy. The patient has been without evidence of disease after 19 months. The presence of PIK3CA, ATM, and IDH2 gene mutations in the reported cases supports the neoplastic nature of BTRPTC, but clinical follow-up suggests an indolent lesion. One unique feature of our report is the next-generation sequencing performed on all the cases. Two of the three cases showed IDH2 gene mutations (cases 1 and 3) . Two of the cases showed ATM (cases 2 and 3), and one case showed PIK3CA gene mutations (case 3). PIK3CA mutations have been identified not only in breast cancers but also in benign proliferative breast lesions such as papilloma (as evident in case 2 of the current series), columnar cell changes, and usual ductal hyperplasia. [17] [18] [19] The significance of PIK3CA mutation in BTRPTC is uncertain but suggests an early but nonspecific event in its neoplastic transformation. The presence of IDH2 mutations identified in two of the three cases deserves special mention. The isocitrate dehydrogenase (IDH) mutation results in loss of normal catalytic activity, production of a-ketoglutarate (a-KG), and gain of a new function, the production of 2-hydroxyglutarate (2-HG), which results in a block in cellular differentiation. 20 These IDH2 mutations have been reported in both benign and malignant tumors; however, to our knowledge, they have not been reported in breast lesions or breast carcinomas. [21] [22] [23] IDH2 mutations are frequently identified in gliomas, where they are considered an early event. In most tumors, IDH2 mutations portend a good prognosis. It has also been suggested that mutant IDH enzymes promote tumorigenesis in the long run but may also cause growth inhibition due to 2-HG toxicity, which also acts as an antagonist of a-KG. 20 So, it is possible that some tumors with IDH mutations (with the absence of other oncogenic mutations) may be somewhat self-limiting. It is to be noted that BTRPTC has also been reported by another name in an abstract form at the 2014 USCAP meeting. 7 This lesion was described as solid papillary neoplasm with reverse polarization (SPNRP) by Chiang et al. 7 SPNRP
shows a similar morphologic and immunohistochemical profile to BTRPTC. The "reverse polarization" refers to the presence of nuclei apically rather than at the basal/stroma aspect. However, nuclei in BTRPTC or SPNRP are more often haphazardly arranged, and this reverse nuclear polarization is more obvious only on careful high-power examination. Chiang et al 8 reported a PIK3CA H1047R mutation in five of nine cases, which is identical to the mutation identified in case 3 of the current study. In another recent abstract at the AACR meeting, the same group revised the name to "solid papillary carcinoma with reverse polarity (SPCRP)" and reported IDH2
R172 hotspot mutations in 10 of 13 cases, with eight of the cases showing concurrent PIK3CA and PIK3R1 mutations. Similar IDH2 mutations are identified in two of the cases in the current report. It appears that our cases are similar to what has been reported by Chiang et al 7, 8 in the two abstracts.
However, using the term carcinoma instead of neoplasm will create confusion with solid papillary carcinoma of the breast, which is an ER-positive, CK5-negative lesion. Another lesion reported in the literature that shares morpho-immunohistologic features with BTRPTC is infiltrating epitheliosis. According to Eusebi and Millis, 24 the lesion shows florid usual ductal hyperplasia (also known as "epitheliosis") that appears to "flow out" into surrounding tissue ("infiltrative"), the hyperplastic epithelium shows frequent but focal squamoid differentiation, and the stroma shows dispersed scleroelastotic changes with keloid-like fibrous bands. Many breast pathologists have observed these lesions in routine practice but have likely classified the lesion into various categories of papillary and sclerosing lesions. Immunohistochemically, the proliferative epithelium of the infiltrating epitheliosis stains diffusely and strongly with basal-type cytokeratins (CK5 or CK5/6) and demonstrate weak/patchy to absent staining for ER, similar to BTRPTC. 25, 26 Recently, Eberle et al 25 reported attenuation or absence of the myoepithelial cell layer around the proliferating cells. This profile is identical to what is observed in BTRPTC. Moreover, Eberle et al 25 reported PIK3CA or PIK3R1 mutations that are also seen in BTRPTC. It appears that there is a continuum between infiltrating epitheliosis and BTRPTC, and they may represent a spectrum of papillary lesions with infiltrating epitheliosis at the sclerosis-rich/epithelial-poor end and BTRPTC at the epithelium-rich/stroma-poor end of the spectrum. In summary, the diagnostic morphologic features of BTRPTC include presence of solid papillary nests of epithelium in a sclerotic stroma, haphazard arrangement of bland epithelial cells with areas demonstrating reverse nuclear polarization, eosinophilic/amphophilic colloid-like secretions, and cells with nuclear grooves and inclusions. The proliferating cells lack peripheral staining for myoepithelial cells, but the cells are strongly positive for CK5, with either weak or no reactivity for ER.
BTRPTC needs to be correctly recognized, and pathologists should not hesitate to use immunohistochemical stains for difficult-to-categorize papillary/sclerosing lesions (Table 4) . BTRPTC is a lesion with an underlying papillary architecture a with mixed epithelial-myoepithelial immunoprofile and few recurrent mutations (in IDH2, ATM, and PIK3CA genes). The clinical findings suggest an indolent lesion but with potential for recurrence with incomplete excision. Therefore, surgeons should plan the surgery to achieve negative margins. At the current time, it is difficult to justify sentinel lymph node procedure, radiation, or systemic therapy. Additional clinicopathologic studies are required to further define appropriate management. 
